We have been made aware of a key meeting in the field of neuroblastoma that clashes with the first appraisal committee meeting, originally scheduled for 26 October 2017, which has severely limited the availability of clinical and patient experts for this appraisal. Given the importance of participation from both clinical and patient experts at the first committee meeting, the decision has been made to move the first discussion to 23 November 2017.